Ann: Prospectus, page-54

https://clinicaltrials.gov/study/NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

@johndprent the paragraph above your quote mentions that only one patient with AML has been treated so far in this trial:
"The trial is the first ever to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. This is the first and currently only patient treated in the blood cancer arm of the Phase 1b trial."
@KrushingIt 's statement is therefore correct, since one of one patient with AML has shown a CR, whilst the other two you are referring to were not part of the blood cancer arm, however also part of this trial.
https://www.listcorp.com/asx/chm/chimeric-therapeutics-limited/news/aml-patient-achieves-complete-response-in-chm-core-nk-trial-3096206.html


CHM also has another AML trial currently recruiting, which is where the confusion may have come from initially:

https://clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

"In the first cohort, which opened to enrolment in Q1 2024, three subjects with relapsed or refractory AML received CHM CORE-NK at Dose Level 1, in combination with standard-of-care aza/ven. No dose-limiting toxicities (DLTs) were reported during the 28-day DLT evaluation period."
https://www.listcorp.com/asx/chm/chimeric-therapeutics-limited/news/phase-1b-advent-aml-trial-of-chm-core-nk-advances-at-mda-3040421.html